Placebo
The Effects of Dietary Supplementation Allicor on Patients With Multifocal Atherosclerosis After Peripheral Artery Revascularization Treatment During a Year
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05813171/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 300 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (05.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 13
Критерии включения
- Age >40 and <75 years
- A revascularization (including stenting, endarterectomy, artery prosthetic or bypass grafting) is indicated for the patient because of chronic atherosclerotic obliteration of the arteries of the lower extremities and/or common carotid arteries.
- Patients passed a complex of instrumental and laboratory examinations before revascularization, including X-ray contrast angiography or ultrasound examination of common carotid arteries and arteries of the lower extremities, the ankle-brachial index (ABI) assessment, biochemical analysis of blood included assessment of cholesterol, triglycerides, low density lipoproteins, high density lipoproteins and glucose levels.
- The possibility of monitoring the patient for 12 months after revascularization, including phone contacts and visits to the clinic after 6 and 12 months.
- Patient or legal authorized representative capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Критерии невключения
- Repeated revascularization surgery.
- Trophic ulcers of the lower extremities.
- Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association).
- Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance < 30 ml / min according to the Cockcroft-Gault Equation)
- High degree of disability of the patient (4 or higher points on the modified Rankin scale).
- History of systemic autoimmune diseases.
- Significant weight loss (> 10% of body weight in the previous year) of unknown etiology.
- Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.).
- Participation in other clinical studies (or use of investigational substances) within 3 months prior to study entry.
- Patients with malignant tumors, including the postoperative period with chemotherapy and/or radiation therapy.
- Carriers of HIV or viral hepatitis
- Pregnancy or breast feeding
- Refusal to participate in the study.
Источник: ClinicalTrials.gov, NCT05813171 · запись обновлена в реестре 19 апреля 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 6
- Frequency of fatal cardiovascular events — Evaluated in 12 months from revascularization interventions
- Frequency of clinically significant cardiovascular events — Evaluated in 12 months from revascularization interventions
- Frequency of indications for a second revascularization — Evaluated in 12 months from revascularization interventions
Цель исследования
A significant challenge in medical care is atherosclerotic occlusion of peripheral arteries, such as lower extremities and brachiocephalic arteries, which can eventually lead to loss of limbs or fatal ischemic strokes. Revascularizing surgical interventions can restore the lumen of the arteries and provide an effective way to treat such patients. However, up to a third of patients need re-intervention or experience cardiovascular complications within a year after surgery. The purpose of this study is to evaluate the effect of adding the natural dietary supplement Allicor to conventional treatment on the incidence of cardiovascular complications and treatment effectiveness 12 months after revascularization. Another valuable area of investigation is the search for predictors of long-term cardiovascular complications after revascularization, which could be markers of inflammation and heteroplasmy levels in the patient's mitochondrial genome.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05813171 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.